EG BioMed is proud to announce two groundbreaking advancements in cancer detection: the EG-Breast blood test and the EG-Pancreatic blood test. These innovative tests are designed to identify breast and pancreatic cancers at an early stage without the need for radiation or invasive procedures. Each test requires only a single 10 mL blood sample, which can be taken at any time, with no limitations on screening frequency.
Featuring an automated analysis workflow that reduces human error, results are delivered within one day through an integrated Customer Relationship Management system. The qPCR-based detection methods are versatile, enabling straightforward implementation in any LDTS lab or clinic. This cutting-edge approach paves the way for rapid global deployment and sets a new benchmark in cancer screening and diagnostics.